Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Method for preparing genetically-modified t cells which express chimeric antigen receptor

A chimeric antigen receptor, gene modification technology, applied in receptor/cell surface antigen/cell surface determinant, fusion cells, cells modified by introducing foreign genetic material, etc., can solve the problem of low gene transfer efficiency and cell damage , cell viability, decreased cell proliferation rate, etc.

Active Publication Date: 2018-06-08
NAT UNIV CORP TOKAI NAT HIGHER EDUCATION & RES SYST
View PDF14 Cites 4 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Although the transposon method can carry out long-lasting gene transfer similarly to the viral vector method, there are the following problems: compared with the viral vector method, the gene transfer efficiency is low, and in addition, the cells follow the gene transfer operation (electroporation and its improved method, etc.) ) was damaged, cell survival rate, cell proliferation rate decreased

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Method for preparing genetically-modified t cells which express chimeric antigen receptor
  • Method for preparing genetically-modified t cells which express chimeric antigen receptor
  • Method for preparing genetically-modified t cells which express chimeric antigen receptor

Examples

Experimental program
Comparison scheme
Effect test

preparation example Construction

[0095] The preparation method of this mode includes the following steps (i) to (iv). In addition, regarding matters not mentioned (for example, methods for preparing cell populations containing T cells, basic manipulations of stimulation by anti-CD3 The operation of gene introduction, the basic operation of co-cultivation, the recovery method of cells, etc.) are the same as the above-mentioned first production method, therefore, redundant descriptions are omitted, and corresponding descriptions are cited.

[0096] (i) a step of preparing non-proliferative cells retaining viral peptide antigens by stimulating a T cell-containing cell population with an anti-CD3 antibody and an anti-CD28 antibody , obtained by culturing in the presence of viral peptide antigens and incapacitating the proliferative ability

[0097] (ii) A step of obtaining a genetically modified T cell into which a target antigen-specific chimeric antigen receptor gene is introduced by the transposon method

[...

Embodiment

[0115]

[0116] Compared with the case of using a viral vector, the CAR therapy using the transposon method is particularly advantageous in terms of safety. On the other hand, low gene transfer efficiency, easy damage to cells during gene transfer operations (such as electroporation), and a small number of obtained cells are problems. In order to overcome these problems, the following studies have been conducted.

[0117] 1. Materials

[0118] (1) Antibody

[0119] Anti-CD3 antibody (Miltenyi Biotec)

[0120] Anti-CD28 antibody (Miltenyi Biotec)

[0121] (2) culture medium

[0122] TexMACS (Miltenyi Biotec)

[0123] (3) Cytokines

[0124] Recombinant human IL-7 (Miltenyi Biotec company)

[0125] Recombinant human IL-15 (Miltenyi Biotec)

[0126] (4) Viral peptide mixture

[0127] PepTivator (registered trademark) CMV pp65-premium grade, human (Miltenyi Biotec)

[0128] PepTivator (registered trademark) AdV5Hexon-premium grade, human (Miltenyi Biotec company)

[01...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

In order to improve the efficiency of gene introduction in CAR therapy employing a transposon technique, provided is a method for preparing genetically-modified T cells which express a chimeric antigen receptor, comprising: (1) a step for preparing non-proliferative cells obtained by stimulating a group of cells including T cells using an anti-CD3 antibody and an anti-CD28 antibody, and thereafter, subjecting the cells to a treatment for causing the cells to lose their proliferation capability; (2) a step for obtaining genetically-modified T cells into which a target antigen-specific chimericantigen receptor gene has been introduced using a transposon technique; (3) mixing the non-proliferative cells prepared at step (1) with the genetically-modified T cells obtained at step (2), and co-culturing the mixed cells while stimulating the mixed cells using the anti-CD3 antibody and the anti-CD28 antibody; and (4) a step for collecting the cultured cells. Also, provided is a method for preparing genetically-modified T cells which express a chimeric antigen receptor, comprising: (i) a step for preparing non-proliferative cells holding a viral peptide antigen, which cells are obtained bystimulating a group of cells including T cells using an anti-CD3 antibody and an anti-CD28 antibody, and thereafter, subjecting the cells to culturing in the presence of the viral peptide antigen anda treatment for causing the cells to lose their proliferation capability; (ii) a step for obtaining genetically-modified T cells into which a target antigen-specific chimeric antigen receptor gene hasbeen introduced using a transposon technique; (iii) mixing the non-proliferative cells prepared at step (i) with the genetically-modified T cells obtained at step (ii), and co-culturing the mixed cells; and (iv) a step for collecting the cultured cells.

Description

technical field [0001] The invention relates to a preparation method and application of genetically modified T cells expressing chimeric antigen receptors. This application claims priority based on Japanese Patent Application No. 2015-200458 for which it applied on October 8, 2015, All the content of this patent application is incorporated in this specification by reference. Background technique [0002] Gene-modified T cell therapy (CAR therapy) using a chimeric antigen receptor (Chimeric Antigen Receptor; hereinafter also referred to as "CAR") is being clinically used. A CAR typically has a structure in which the single-chain variable region of an antibody is used as an extracellular domain, and a transmembrane region, CD3ζ, and an intracellular domain of a molecule that transmits costimulatory signals are connected to the extracellular domain. By binding to the antigen according to the specificity of the antibody, CAR-T cells are activated to damage target cells (cancer ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): C12N15/09A61K35/17A61P35/00C07K14/705C07K19/00C12N5/10
CPCC07K14/705C07K19/00C12N5/10C12N15/09A61P35/00A61K2239/48A61K39/464412A61K2239/31A61K39/464838A61K39/4631A61K2239/38C12N5/0636A61K39/4611C12N5/0646A61K2039/585C07K14/075C07K14/7051C07K14/70521C12N5/163
Inventor 西尾信博中沢洋三田中美幸盛田大介高桥义行
Owner NAT UNIV CORP TOKAI NAT HIGHER EDUCATION & RES SYST
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products